22q11.2 deletion syndrome

22q11.2 deletion syndrome
ICD-10	D82.1
ICD-9	279.11, 758.32
OMIM	188400
DiseasesDB	3631
eMedicine	med/567  ped/589 derm/716
MeSH	D004062

WikiDoc Resources for 22q11.2 deletion syndrome
Articles
Most recent articles on 22q11.2 deletion syndrome Most cited articles on 22q11.2 deletion syndrome Review articles on 22q11.2 deletion syndrome Articles on 22q11.2 deletion syndrome in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on 22q11.2 deletion syndrome Images of 22q11.2 deletion syndrome Photos of 22q11.2 deletion syndrome Podcasts & MP3s on 22q11.2 deletion syndrome Videos on 22q11.2 deletion syndrome
Evidence Based Medicine
Cochrane Collaboration on 22q11.2 deletion syndrome Bandolier on 22q11.2 deletion syndrome TRIP on 22q11.2 deletion syndrome
Clinical Trials
Ongoing Trials on 22q11.2 deletion syndrome at Clinical Trials.gov Trial results on 22q11.2 deletion syndrome Clinical Trials on 22q11.2 deletion syndrome at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on 22q11.2 deletion syndrome NICE Guidance on 22q11.2 deletion syndrome NHS PRODIGY Guidance FDA on 22q11.2 deletion syndrome CDC on 22q11.2 deletion syndrome
Books
Books on 22q11.2 deletion syndrome
News
22q11.2 deletion syndrome in the news Be alerted to news on 22q11.2 deletion syndrome News trends on 22q11.2 deletion syndrome
Commentary
Blogs on 22q11.2 deletion syndrome
Definitions
Definitions of 22q11.2 deletion syndrome
Patient Resources / Community
Patient resources on 22q11.2 deletion syndrome Discussion groups on 22q11.2 deletion syndrome Patient Handouts on 22q11.2 deletion syndrome Directions to Hospitals Treating 22q11.2 deletion syndrome Risk calculators and risk factors for 22q11.2 deletion syndrome
Healthcare Provider Resources
Symptoms of 22q11.2 deletion syndrome Causes & Risk Factors for 22q11.2 deletion syndrome Diagnostic studies for 22q11.2 deletion syndrome Treatment of 22q11.2 deletion syndrome
Continuing Medical Education (CME)
CME Programs on 22q11.2 deletion syndrome
International
22q11.2 deletion syndrome en Espanol 22q11.2 deletion syndrome en Francais
Business
22q11.2 deletion syndrome in the Marketplace Patents on 22q11.2 deletion syndrome
Experimental / Informatics
List of terms related to 22q11.2 deletion syndrome

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

22q11.2 deletion syndrome, also known as Velocardiofacial Syndrome, Di George Syndrome and Strong Syndrome is a disorder caused by the deletion of a small piece of chromosome 22. The deletion occurs near the middle of the chromosome at a location designated q11.2. It has a prevalence estimated at 1:4000.

Presentation

The features of this syndrome vary widely, even among members of the same family, and affect many parts of the body. Characteristic signs and symptoms include heart defects that are often present from birth, an opening in the roof of the mouth (a cleft palate or other defect in the palate), autism, other learning disabilities, mild differences in facial features, and recurrent viral or fungal infections are common due to problems with the immune system's T-cell mediated response. DiGeorge syndrome is often first spotted when the affected newborn begins convulsing from hypocalcemia due to an absence of parathyroid and parathyroid hormone. Affected individuals may also have kidney abnormalities, significant feeding difficulties, autoimmune disorders such as rheumatoid arthritis, and an increased risk of developing mental illnesses. Microdeletions in chromosomal region 22q11 are associated with a roughly 30-fold increased risk of schizophrenia, and are frequently detected in schizophrenic patients. Different studies provide different occurrence rates, ranging from 0.5 to 3%, compared with the overall 0.025% risk of the 22q11 deletion syndrome in the general population.

Nomenclature

Because the signs and symptoms of 22q11.2 deletion syndrome are so varied, different groupings of features were once described as separate conditions. These included the velo-cardio-facial syndrome (also called Shprintzen's syndrome), DiGeorge syndrome, hearing loss with craniofacial syndromes and conotruncal anomaly face syndrome, thymic hypoplasia, cleft palate, psychiatric disorders, and hypocalcaemia. The acronym CATCH-22 (C = cardiac defects, A = abnormal facies, T = thymic hypoplasia, C = cleft palate, H = hypocalcemia from parathyroid aplasia, 22 = microdeletions in chromosome 22) is sometimes used, although it is widely rejected because of the negative connotations with Catch-22 meaning a 'no-win' situation.

In addition, some children with the 22q11.2 deletion were diagnosed with Opitz G/BBB syndrome and Cayler cardiofacial syndrome. Once the genetic basis for these disorders was identified, doctors determined that they were all part of a single syndrome with many possible signs and symptoms. To avoid confusion, this condition is usually called 22q11.2 deletion syndrome, a description based on its underlying genetic cause.

Symptoms

Individuals with a 22q11 deletion can suffer from a range of over 200 possible symptoms, ranging from the mild to the very serious. Possible symptoms are:

• Congenital heart disease (74% of individuals), particularly conotruncal malformations (tetralogy of Fallot, interrupted aortic arch, ventricular septal defect, and persistent truncus arteriosus)
• palatal abnormalities (69%), particularly velopharyngeal incompetence (VPI), submucosal cleft palate, and cleft palate; characteristic facial features (present in the majority of Caucasian individuals) including hypertelorism.
• learning difficulties (70-90%)
• an immune deficiency regardless of their clinical presentation (77%)
• hypocalcemia (50%)(due to hypoparathyroidism)
• significant feeding problems (30%)
• renal anomalies (37%)
• hearing loss (both conductive and sensorineural) (Hearing loss with craniofacial syndromes)
• laryngotracheoesophageal anomalies
• growth hormone deficiency
• autoimmune disorders
• seizures (without hypocalcemia)
• skeletal abnormalities
• Autism and Autism spectrum disorders

Thymus, parathyroid glands and heart derive from the same primitive embryonic structure and that is why these three organs are dysfunctioned together in this disease. Affected patients (usually children) are prone to yeast infections.

Cause

The syndrome is caused by genetic deletions (loss of a small part of the genetic material) found on the long arm of the 22nd chromosome. Some patients with similar clinical features may have deletions on the short arm of chromosome 10.

DiGeorge syndrome causes migration defects of neural crest-derived tissues, particularly affecting development of the third and fourth Branchial pouches (pharyngeal pouches). Also affected is the thymus gland; a mediastinal organ largely responsible for differentiation and induction of tolerance in T-cells. Impaired immune function results principally from this aetiology.

Treatment

Although genetic transplantation methods are currently being developed by researchers, there is yet no genetic treatment of this disease.

It is important that the immune problems are identified early as special precautions are required regarding blood transfusion and immunisation with live vaccines.

Treatment is largely symptomatic, infections are treated with antibiotics, and these patients may undergo cardiac surgery for their heart abnormalities. Hypoparathyroidism causing hypocalcaemia is often transient, but may require lifelong vitamin D treatment.

Thymus transplantation can be used to address absence of the thymus in complete DiGeorge syndrome.

Diagnosis/testing

The 22q11.2 deletion syndrome is diagnosed in individuals with a submicroscopic deletion of chromosome 22 detected by fluorescence in situ hybridization (FISH) using DNA probes from the DiGeorge chromosomal region (DGCR). Such genetic testing is widely available for the clinical and prenatal testing of the 22q11.2 deletion syndrome. Fewer than 5% of individuals with clinical symptoms of the 22q11.2 deletion syndrome have normal routine cytogenetic studies and negative FISH testing. They may have variant deletions of DiGeorge syndrome that may be detectable on a research basis only.

Genetics

22q11.2 deletion syndrome is inherited in an autosomal dominant pattern.

Most people with 22q11.2 deletion syndrome are missing about 3 million base pairs (the building blocks of DNA) on one copy of chromosome 22 in each cell. This region contains about 30 genes, but many of these genes have not been well characterized. A small percentage of affected individuals have shorter deletions in the same region. This condition is often described as a contiguous gene deletion syndrome because a deletion in chromosome 22 leads to the loss of many genes.

Researchers have not yet identified all of the genes that contribute to the features of 22q11.2 deletion syndrome. They have determined that the loss of one particular gene on chromosome 22, TBX1, is probably responsible for many of the syndrome's characteristic signs (such as heart defects, a cleft palate, distinctive facial features, and low calcium levels). A loss of this gene does not appear to cause learning disabilities, however. Additional genes in the deleted region are likely to contribute to the signs and symptoms of 22q11.2 deletion syndrome.

The 22q11.2 deletion syndrome can be inherited in an autosomal dominant manner. Almost all (about 93%) of cases have a de novo (new to the family) deletion of 22q11.2 but about 7% inherit the 22q11.2 deletion from a parent. Children of an individual with deletion 22q11.2 have a 50% chance of inheriting the 22q11.2 deletion. Prenatal testing, such as amniocentesis, is available for pregnancies determined to be at risk. Also pregnancies who have findings of congenital heart disease and/or cleft palate detected by ultrasound examination may be offered prenatal testing. Genetic counseling may be helpful for families who may have DiGeorge syndrome. Because most of the signs of this cluster of defects can also be inherited as autosomal recessive or x-linked traits, only genetic testing of both parents can determine with any certainty the likelihood these anomalies occurring in any subsequent children.

Epidemiology

22q11.2 deletion syndrome affects an estimated 1 in 4000 live births . The condition may be more common, however, because some people with the deletion have few signs and symptoms and may not have been diagnosed.

Cognitive and language problems

Cognitive deficits

Children with 22q11.2 have a specific profile in neuropsychological tests. They usually have a low IQ (50-80) but with better verbal than procedural functions. Especially big problems are usually within arithmetic and executive skills. Familial transmission of the disease seems to result in worse cognitive impairments than the de novo cases. It has been speculated that the observed cognitive problems arise from visuo-spatial problems.

Noteworthy is that these patients are a specifically high-risk group for developing schizophrenia. 30% have at least one incident of psychosis and about a quarter develop actual schizophrenia.

Speech and Language

Current research demonstrates there is a unique profile of speech and language impairments associated with 22q11.2 deletion syndrome. Children often perform lower on speech and language evaluations in comparison to their nonverbal IQ scores. Common problems include hypernasality, language delays, and speech sound errors.

Hypernasality occurs when air escapes through the nose during the production of oral speech sounds resulting in reduced intelligibility. This is a common characteristic in the speech and language profile because 69% of children have palatal abnormalities. If the structure of the soft palate velum is such that it does not stop the flow of air from going up to the nasal cavity, it will cause hypernasal speech. This phenomenon is referred as velopharyngeal inadequacy VPI. Hearing loss can also contribute to increased hypernasality because children with hearing impairments can have difficulty self monitoring their oral speech output. The treatment options available for VPI include prosthesis and surgery.

Difficulties acquiring vocabulary and formulating spoken language (expressive language deficits) at the onset of language development are also part of the speech and language profile associated with the 22q11.2 deletion. Vocabulary acquisition is often severely delayed for preschool age children. In some recent studies, children had a severely limited vocabulary or were still nonverbal at 2-3 years of age. School age children do make progress with expressive language as they mature, but many continue to have delays and demonstrate difficulty when presented with language tasks such as verbally recalling narratives and producing longer and more complex sentences. Receptive language, which is the ability to comprehend, retain, or process spoken language, can also be impaired although not usually with the same severity as expressive language impairments.

Articulation errors are commonly present in children with 22q11.2 deletion syndrome. These errors include a limited phonemic (speech sound) inventory and the use of compensatory articulation strategies resulting in reduced intelligibility. The phonemic inventory typically produced consists of sounds made in the front or back of the vocal tract such as: /p/, /w/, /j/, /m/, /n/, and glottal stops. Mid vocal tract sounds are completely absent. Compensatory articulation errors made by this population of children include: glottal stops, nasal substitutions, pharyngeal fricatives, linguapalatal sibilants, reduced pressure on consonant sounds, or a combination of these symptoms. Of these errors, glottal stops have the highest frequency of occurrence. It is reasoned that a limited phonemic inventory and the use of compensatory articulation strategies is present due to the structural abnormalities of the palate. The speech impairments exhibited by this population are more severe during the younger ages and show a trend of gradual improvement as the child matures.

See also

• Asymmetric crying facies

References

This article incorporates public domain text from The U.S. National Library of Medicine

External links

• GeneReviews: 22q11.2 deletion syndrome
• India Knight's blog about children with special needs. Her daughter suffers from 22q11.2 Deletion Syndrome
• VCFS Educational Foundation, Inc.
• Children's Hospital of Philadelphia
• NIH
• MaxAppeal
• International 22q11.2 Deletion Syndrome Foundation
• Asoc. Familias 22q11 DS/VCFS

Template:WikiDoc Sources